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ABSTRACT
By infecting mice with the yellow fever virus vaccine strain 17D (YFV-17D; Stamaril®), the dose dependence and
evolutionary consequences of neurotropic yellow fever infection was assessed. Highly susceptible AG129 mice were
used to allow for a maximal/unlimited expansion of the viral populations. Infected mice uniformly developed
neurotropic disease; the virus was isolated from their brains, plaque puriﬁed and sequenced. Viral RNA populations
were overall rather homogenous [Shannon entropies 0−0.15]. The remaining, yet limited intra-host population
diversity (0−11 nucleotide exchanges per genome) appeared to be a consequence of pre-existing clonal
heterogeneities (quasispecies) of Stamaril®. In parallel, mice were infected with a molecular clone of YFV-17D which
was in vivo launched from a plasmid. Such plasmid-launched YFV-17D had a further reduced and almost clonal
evolution. The limited intra-host evolution during unrestricted expansion in a highly susceptible host is relevant for
vaccine and drug development against ﬂaviviruses in general. Firstly, a propensity for limited evolution even upon
infection with a (very) low inoculum suggests that fractional dosing as implemented in current YF-outbreak control
may pose only a limited risk of reversion to pathogenic vaccine-derived virus variants. Secondly, it also largely lowers
the chance of antigenic drift and development of resistance to antivirals.
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Introduction
Yellow fever (YF) is an acute haemorrhagic disease
caused by the yellow fever virus (YFV), an enveloped,
positive-sense RNA virus that belongs to the genus Fla-
vivirus. Other clinically important ﬂaviviruses include
the dengue (DENV), Zika (ZIKV), West Nile
(WNV), tick-borne encephalitis (TBEV) and Japanese
encephalitis (JEV) viruses. Their genome encodes for
a single polyprotein that is co- and post-translationally
processed into 3 structural proteins and 7 non-struc-
tural proteins (NS1-5), the latter responsible for intra-
cellular replication of the viral RNA genome. The open
reading frame (ORF) is ﬂanked by untranslated regions
(UTR) at the 5’ and 3’ ends, respectively.
YFV infects humans in Africa and South America
causing an estimated 84000–170000 severe cases and
29000–60000 deaths per year, with 90% of cases occur-
ring in Africa [1], and the potential threat to global
health with introduction into new areas via travellers
is greater than ever [2, 3]. Accurate data about YF bur-
den are diﬃcult to obtain because of underreporting,
limitated passive surveillance, lack of diagnostic capacity
in many regions where YF is endemic [4], and occur-
rence of asymptomatic infection [5, 6]. Given the lack
of eﬀective vector control, the most eﬀective strategy
to prevent and control yellow fever is by active immu-
nization with high population coverage rates [7].
WHO-prequaliﬁed yellow fever vaccines include the yel-
low fever virus 17D (YFV-17D) prototype vaccine
strain, or the YFV-17DD substrain derived thereof.
The YFV-17D strain was originally derived from a clini-
cal isolate (Asibi strain) and attenuated by serial passa-
ging in the early 1930s [8, 9]. The live-attenuated
YFV-17D is considered as one of the most eﬃcient vac-
cines ever developed with long immunogenicity [10, 11].
It induces a vigorous, multi-speciﬁc and possibly life-
long lasting protective immunity in >95% of the vacci-
nees within 10 days after vaccination [12,13].
YFV-17D has a long-standing historic record and a
favourable safety proﬁle [14–16] (about 850 million
doses deployed since 1937). All six YF vaccines used
today belong to either of the two main sublineages of
the original 17D vaccine, 17D-204 and 17DD [17] of
which four are prequaliﬁed by WHO including the
particular 17D-204 vaccine produced in France and
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licensed under the trade name Stamaril® (Sanoﬁ-Pas-
teur). However, it also has several drawbacks that ham-
per its wider use in mass vaccination campaigns,
particularly in remote and poorly developed areas: (i)
its tedious production in embryonated chicken eggs,
(ii) lot-to-lot variabilities posing potential safety con-
cerns of loss of attenuation and reversion to increased
virulence, (iii) the inherent thermal instability requir-
ing a cold chain and (iv) the need for needles for par-
enteral delivery. To circumvent these drawbacks, we
developed a plasmid (WO2014174078A1) that allows
the convenient direct launching of the YFV-17D viral
genome (and that of other RNA viruses) upon injection
in the host (WO2014174078A1).
RNA viruses typically replicate to diverse groups of
“quasispecies” populations wherein viral diversity may
correlate with virulence and pathogenicity, as studied
mainly using the poliovirus paradigm [18–22,23]. A
major concern for any live-attenuated RNA virus vac-
cine (such as the YFV-17D) is the emergence of virus
variants that lose their attenuation and revert to high
virulence. YFV-17D has been empirically developed
more than 80 years ago, yet is today still the only vac-
cine platform to control YFV outbreaks [24]. For vac-
cine production YFV-17D is grown in a hard to control
process in embryonated chicken eggs. The entire pro-
cess is strictly regulated by WHO recommendation cri-
teria and needs to follow a historically established seed-
lot system; continuous quality control involves consist-
ency testing to avoid genetic drift, including mandatory
testing for neurovirulence and viscerotropic replication
potential in non-human primates. Rare but severe
adverse eﬀects (SAE) have been reported for YFV-
17D, in particular yellow fever vaccine-associated vis-
cerotropic (YEL-AVD) and neurotropic disease
(YEL-AND) [14,25]. Though poorly understood,
pathogenesis of YEL-AVD is mostly related to a predis-
position of the individual vaccinee, such as functional
thymus deﬁciencies or haematological disorders, and
likely not to viral factors, in particular not to virus var-
iants emerging from the vaccine virus quasispecies
[25,26]. However, for YEL-AND there is good evidence
that an increased virulence of some minority variants
that emerge after inoculation and start to dominate
the replicating vaccine population may be more
directly linked to neurovirulence [27]. The vaccine
studied here was of the YF17D-204 lineage that had
been reported to be very stable and to accumulate
only very few mutations during large-scale production
[28]. It is further recognized as one of the YFV-17D
vaccines with the lowest reported incidence of SAE
[26]. The primary goal of the current study is to assess
the genetic stability and diversity (mutation rates and
patterns) of YFV-17D during its replication in a ver-
tebrate host. To this end, we used mice deﬁcient in
IFN α/β and γ receptors (AG129) that are highly sus-
ceptible to YFV, including YFV-17D, and allow
maximal expansion of the viral population in the
absence of a protective immune response. The evol-
ution of live-attenuated YFV-17D virus was also mon-
itored when the virus was launched as molecular clone
from a plasmid (herein called PLLAV, plasmid-
launched live-attenuated virus).
Materials and methods
Plasmids
Plasmid pShuttle/YFV-17D (WO2014174078A1)
[29,30] is a derivative of pBeloBAC11 that carries a
YFV-17D cDNA copy (17D-204 strain from ATCC,
Genbank Genbank X03700.1) ﬂanked at the 5’ by a
SV40 promoter, and at the 3’ end by a hepatitis delta
virus ribozyme. A second conditional origin allows
for increased plasmid yields in E. coli EPI300-T (Epi-
centre) [31]. When used for immunization, pShuttle/
YFV-17D is dubbed Plasmid-Launched Live-Attenu-
ated Virus Vaccine (PLLAV). PLLAV was formulated
for i.p. injection in 33% v/v 1,2-propanediol containing
17% w/v calcium carbonate microﬂowers as previously
described [32].
Virus stocks
YFV-17D was derived from the commercial YFV-17D
vaccine (Stamaril®, Sanoﬁ-Pasteur MSD, Brussels, lot
H5105). For the generation of virus stocks, 106 BHK-
21J cells [33] were inoculated with 100 µL of Stamaril®
diluted into 20 mL MEM/2% FBS, incubated for 1 h at
room temperature, and incubated with 40 mL fresh
medium at 37 °C, 5% CO2 for viral growth. After 7
days, virus-containing supernatant was harvested by
centrifugation at 400xg for 10 min and stored at
−80 °C for further use. The infectious content was
determined by plaque assay (see infra) with one pla-
que-forming unit (PFU) equalling 10–100 median
cell culture infectious doses (CCID50), The infectious
content was determined by plaque assay (see infra)
with one plaque-forming unit (PFU) equalling 10–
100 median cell culture infectious doses (CCID50)
[approximately 10 International Units (IU) [34]
although virus stocks were not back-titrated against
the WHO potency standard (NIBSC Code 99/616)].
Mice and tissue samples
Brains sections of AG129 mice [35] that had been
inoculated intraperitoneally with either 104 PFU
(Brains 2, 3, and 4), 10−1 PFU (Brains 9 and 10),
10−2 PFU (Brain 11) of YFV-17D derived from Sta-
maril®, or 20 µg of PLLAV-YFV-17D (Brains 5, 6, 8,
12, 13, 14, and 15) were stored frozen at −80 °C.
Mice were euthanized as soon as overt signs of viral
encephalitis (sudden weight loss, hindlimb paralysis,
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hunched posture) were observed. YFV-17D RNA was
detected by quantitative RT–PCR using primers and
probes (Table S3) as decribed [36].
Genome ampliﬁcation
Viral genomes extracted from cell culture supernatants
(NucleoSpin RNA, Macherey-Nagel) and brain sec-
tions (RNeasy Mini, Qiagen) were ampliﬁed by RT–
PCR (qScript One-Step RT–PCR, Quanta Bioscience)
as overlapping 2 kb amplicons using primers (Table
S1) as described [37]. RT–PCR conditions were as fol-
lows: RT at 48°C for 20, 3 min at 95°C, and 40 cycles of
at 94°C for 30 s, at 60°C for 30 s, and at 72°C for 2 min,
and ﬁnal extension at 72°C for 10 min. Amplicons were
gel puriﬁed and subjected to direct Sanger sequencing
(BigDye v3.1).
Sequence analysis
For de novo assembly of viral genomes, sequences were
submitted to SeqScape v2.6, trimmed from both ends
and aligned to the reference YFV-17D genome (Gen-
bank X03700.1) (Supplementary Table S6), excluding
reads with low quality and/or few nucleotides (less
than 200 bp). Final alignments were corrected manu-
ally. Mega X [38] was used for phylogenetic analysis
and to construct phylogenetic trees.
Full-length consensus genomes generated for (i) Sta-
maril® (lot H5105), (ii) for the vaccine passaged once
and twice on BHK-21J cell (reﬂecting viral ampliﬁcation
and adaptation during plaque puriﬁcation), and (iii) of
representative clones of major bona ﬁde variants present
in Stamaril® were submitted to NCBI-Genbank
with accession numbers MN708488 – MN708497
(Supplementary Table S7).
Measurement of absolute diversity
Viral diversity was measured by (i) the mutation fre-
quency (mutant clones divided by the total number
of clones analyzed) (ii) the Shannon entropy [39–41],
(iii) the Simpson index of diversity (1-D) [42] and
(iv) the Hamming distances [43–45]. Shannon entropy
of each brain was calculated using the following for-
mula [40]:
sn = −S
n
i=1fi(ln fi)
N
Where n is the number of diﬀerent species identiﬁed, ﬁ
is the observed frequency of a particular variant in the
quasispecies, and N is the total number of clones ana-
lyzed [40,41,46]. The Simpson index of diversity was
calculated as:
D =
∑
n(n− 1)
N(N − 1)
Where n is the total number of variants of a particular
species, and N the total number of variants in the
population.
Plaque assay and plaque puriﬁcation
Serial dilutions (1/50–1/31250) of brain homogenates
(in MEM/ 2% FBS) were added to 106 cells/well of
BHK-21J cells grown in 6-well plates. Virus was
removed after 1 h at 37°C, cells washed 3 times with
PBS, and overlaid with 3 ml of 0.5% low melting agar-
ose (Invitrogen) in MEM/2% FBS. After 7 days at 37°C
for, cells were stained with 1% MTT (3-[4,5-
Dimethylthiazol-2-yl]−2,5-Diphenyltetrazolium Bro-
mide) at room temperature for up to 1 h. Agar from
visible plaques were punched out randomly, disregard-
ing any diﬀerences in plaque phenotype (size or colour-
ing), dissolved in 1 mL of MEM/2% FBS by vortexing,
followed by centrifugation at 2000xg for 5 min. For
virus ampliﬁcation, 500 µl of plaque supernatant was
used to infect 106 BHK-21J cells in 6-well plates. At
day 4 post infection, virus supernatants were harvested
and stored at −80°C for RNA isolation.
Statistical analysis
All data were analyzed using GraphPadPrism v7 or R
[45] and results expressed as mean values ± standard
error of mean (SEM). Comparison between groups
was performed using Mann–Whitney test with Bonfer-
roni’s correction, and p-values <0.05 were considered
statistically signiﬁcant. *P = 0.05; **P < 0.01; ***P <
0.001; ****P < 0.0001, ns = not signiﬁcant.
Results
Genetic stability of YFV-17D and plasmid-
launched YFV-17D following inoculation of
AG129 mice.
To investigate the evolution of YFV-17D and plasmid-
launched YFV-17D in mice, six to eight weeks old
AG129 mice were inoculated intraperitoneally with
either 10−2 (corresponding to ∼1 CCID50), 10−1 or
104 PFU (> 105 CCID50) of YFV-17D, or with 20 µg
of the PLLAV-YFV-17D plasmid (n = 2, 1, 3, and 7,
respectively); infectious titres and viral RNA loads in
mouse brains at the time point of euthanasia (when
mice presented with signs of encephalitis, such as
hunched posture, limping and paralysis) were deter-
mined by plaque assay and qRT-PCR, respectively
(Supplementary Figure S1). One out of 2 mice inocu-
lated with 10−2 (corresponding to ∼1 CCID50) did
not develop any overt signs of disease, had no detect-
able viruses in the brain, nor seroconverted (data not
shown), and was excluded from further analysis. For
each brain at least n = 6 (6–15) individual plaques
1736 D. B. Kum et al.
(Supplementary Table S1) were independently
expanded and subjected to direct Sanger sequencing
(Figure 1A). In total, 73 full virus genomes from the
brains of six mice that had been inoculated with
YFV-17D were analysed, each comprising in total
10862 nucleotides and collectively resulting in the
identiﬁcation of 46 distinct nucleotide changes as com-
pared to the consensus sequence of Stamaril® that had
been used as the virus inoculum (Supplementary Table
S4). Generally, the nucleotide variants observed in the
individual plaque-puriﬁed virus clones were scattered
along the E, NS1, NS2A, NS3, NS4B, NS5 and 3’
UTR genomic regions (Figure 1B, Table 1). No
mutations were observed in the 5’ UTR and capsid
genes of one YFV-17D variants (Figure 1B, Table 1).
This equal distribution suggests that there are no hot-
spots for mutations in the YFV-17D genome during
replication and neuroinvasion in mice: the observed
mutation rate per gene was comparable (between
10−4 and 10−3 substitutions per gene; Table 1) with
no signiﬁcant diﬀerences among all condition neither
for Shannon nor Simpson entropies (p-values >0.05,
Mann–Whitney), and hence no evidence for the selec-
tion of mutations that could be linked to neurotropism
or neurovirulence [48]. The overall nucleotide substi-
tution rate per viral genome was between 10−4 and
10−5, in support of the relatively low mutation rates
reported for yellow fever vaccine virus [36,49] as com-
pared to other RNA viruses [50,51], especially consid-
ering the prolonged time between inoculation and
euthanasia (13–18 days, median = 16 days) available
for expansion of the virus populations.
No mutations were observed in 12% (9/73) of brain-
derived YFV-17D clones, while the remaining 88%
(64/73) carried at least one mutation (Figure 2).
Viruses with no mutations in their genomes were
exclusively isolated from a mouse that was injected
with the high(est) inoculum, 104 PFU (Figure 2A,
Brain 2). In the brain of mice that had been injected
with a low titre of the vaccine virus, increased mutation
rates were noted (Figure 3A,B); the highest number of
mutations were recorded in a mouse that had been
inoculated with 10−2 PFU of Stamaril®-derived YFV-
17D (Figure 2A, Brain 11).
As was the case for the YFV-17D infected mice, in
mice that had been inoculated with PLLAV-YFV-
17D, nucleotide changes observed in brain-derived
viruses were scattered throughout the E, NS1, NS2A,
NS3, NS4A and NS5 regions (Figure 1B, Table 1).
Forty-two percent (42%) (36/86) of virus clones that
were plaque-puriﬁed from the brain of mice that had
been inoculated with PLLAV-YFV-17D had no
mutations (Figure 2B) (in contrast to 12% observed
in YFV-17D inoculated mice, Figure 2A) whereas the
remaining 58% (50/86) had either only 1 or 2
mutations (median = 1) per genome. Hence the inci-
dence of nucleotide variants in the PLLAV-YFV-17D
derived viruses was markedly lower compared to the
frequency of variant clones that were obtained from
mice that had been injected with YFV-17D (Stamaril®);
Figure 1.Mutation spectrum of YFV-17D and PLLAV following infection in AG129 mice. (A) Schematic presentation of study design.
AG129 mice were inoculated i.p. with either a range of inocula of YFV-17D; 10−2–10−1 PFU, or 104 PFU of YFV-17D (n = 3/group) or
with 20 µg of PLLAV (n = 7). Mice brains were harvested and homogenized for plaque puriﬁcation prior to sequencing. (B) Mutation
frequencies in brain-derived YFV-17D and PLLAV following neurotropic infection in AG129 mice.
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where 0–11 mutations per genome (median = 5) were
observed (Figure 2B).
Impact of the YFV-17D inoculum size on
evolution of the virus in AG129 mice
It was next investigated whether the YFV-17D popu-
lation diversity may be a function of inoculum size
and diﬀered in mice that were infected with a
(very) low inoculum of the vaccine virus instead of
a high viral dose. Importantly, the pathogenesis
induced by YFV-17D was highly similar and inde-
pendent of the inoculum size, as conﬁrmed by similar
viral brain RNA loads at euthanasia (Supplementary
Figure S1) and no obvious changes in plaque pheno-
type in viruses isolated from respective mouse brains
(not shown). Nevertheless, neuroinvasion and pro-
gression to neurotropic disease took longer in mice
in the low inoculum group; surviving on average
longer (16–18 days to euthanasia) compared to the
high inoculum group (13–16 days to euthanasia; no
signiﬁcant diﬀerence). As a very low inoculum may
allow the maximal expansion of the populations
and thus a maximal likelihood to accumulate
mutations, data from mice injected with either a
high (104 PFU) or low (10−1 or 10−2 PFU) inoculum
of YFV-17D were directly compared. Data from mice
inoculated with 20 µg of PLLAV-YFV-17D and using
a molecular clone of YFV-17D were included as
benchmark. Diversity was measured by Hamming
distance, Shannon entropy and Simpson diversity
index (Figure 3A–D).
The Hamming distance [43–45] (Figure 3A,B)
measures the number of nucleotide substitutions in
viral genomes and group variants based on the number
of substitutions when compared with the reference
sequence (GenBank X03700). Clones with the same
number of mutations are grouped together. The type
of mutation or its position in the genome is not
taken into consideration in this analysis. A signiﬁcant
diﬀerence in Hamming distances between the high
and low titre YFV-17D inocula were noted (p <
0.001). The highest individual diversity was observed
in one particular mouse injected with as little as 10−2
PFU (∼1 CCID50). For further analysis, the clones
obtained from the brain of this mouse (n = 15) were
grouped with those retrieved from two mice that had
been inoculated with 10−1 PFU of the vaccine virus
(together collectively named the “low inoculum”).
Clones from the low inoculum group had between 1
and 11 nucleotide substitutions per genome (Figure
3A). Supportive, though not signiﬁcantly diﬀerent,
there was a consistent trend for a greater diversity in
the low inoculum group also regarding Shannon
entropy (Figure 3C) and Simpson diversity index
(Figure 3D). A higher mutation rate in the low inocu-
lum group could most likely be attributed to the
increased number of replication cycles of the inocu-
lated virus. Regardless of the titre of the inoculum,
the mutation rates of the virus clones did not exceed
10−4 substitutions per genome, underscoring the stab-
ility of the YFV-17D genome.
YFV-17D passes through a bottleneck during
neuroinvasion in AG129 mice
For the poliovirus, it has been demonstrated that bottle-
necks restrict the spread of viral variants from the injec-
tion site to the brain [18, 19]. We set out to explore
whether a similar bottleneck exists for YFV-17D. To
that end, the infection model in AG129 mice is ideally
suited because it allows for suﬃcient replication and
traﬃcking of the virus from the injection site (i.p.) to
(also) the brain. Prior to inoculation in AG129 mice,
the initial YFV-17D (Stamaril®) virus stock was
characterized by Sanger sequencing (Supplementary
Figure S2). In addition, virus clones (n = 20) were pla-
que-puriﬁed from BHK-21J cells that had been infected
with Stamaril® and were ampliﬁed once on BHK-21J
cells prior to whole viral genome sequencing
(Figure 4A). Both plaque-puriﬁed Stamaril® clones (Sup-
plementary Table S4) and plaque-puriﬁed YFV-17D
Table 1. Nucleotide substitutions per genomic region of YFV-17D versus PLLAV
Gene
Mutation rate Mutation rate
# of Nucleotide changes* YFV-17D # of Nucleotide changes PLLAV
5’ UTR 0 0 1 8.47E × 10−3
Capsid protein 0 0 1 2.75E × 10−3
prM/M 1 4.06 × 10−3 1 4.06E × 10−3
E 7 4.73 × 10−3 1 6.8E × 10−3
NS1 4 3.34 × 10−3 5 4.0E × 10−3
NS2A 3 6.0 × 10−3 2 4.0E × 10−3
NS2B 1 2.56 × 10−3 0 0
NS3 8 4.81 × 10−3 3 1.16 × 10−3
NS4A 3 3.48 × 10−3 2 2.32 × 10−3
NS4B 3 8.93 × 10−3 0 0
NS5 14 5.15 × 10−3 4 1.47 × 10−3
3’ UTR 3 5.89 × 10−3 1 1.96 × 10−3
*Sum total of all nucleotide changes observed in the virus population regardless of YFV-17D dose administered. Mutation rates were calculated by dividing
the number of mutations observed in each genomic region by the number of nucleotides that constitute the genomic region. Pairwise comparison of the
Shannon and Simpson entropy per genome region for each of the conditions (Stamaril® low and high, PLLAV) revealed no signiﬁcant diﬀerences in entropy
between regions (p-values >0.05, Mann-Whitney test).
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Figure 2.Mutation patterns observed in YFV-17D infected mice. (A) Graphical presentation of genomes of 73 brain-derived, plaque-
puriﬁed virus clones of YFV-17D following i.p. inoculation and neuroinvasion in AG129 mice (n = 6). (B) Graphical presentation of 86
similar virus clones following i.p. injection of 20 µg of PLLAV-YFV17D and neuroinvasion in AG129 mice (n = 7). Horizontal blue lines
represent individual YFV-17D genomes with blue circles as 5’ and 3’ UTRs, respectively. Red, green and orange diamonds represent
missense, silent and mixed mutations, respectively (mixed = parental + mutant nucleotide). For a full list of mutations see Sup-
plementary Tables S4 and S5.
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clones from mouse brains (Figure 5A, B, Supplementary
Figure S3) appear to be highly heterogeneous (diﬀerent
variants) (Supplementary Table S5). By comparing the
sequences of 20 diﬀerent randomly picked YFV-17D
clones plaque-puriﬁed from Stamaril® directly in vitro
(Figure 4A), we hypothesize that Stamaril® comprises at
least 5 (major) virus variants, and the dominant virus
variants isolated subsequently from infected mouse
brains seem to an large extent to pre-exist in the hetero-
geneous Stamaril® population (Figure 4B, Supplementary
Tables S7 and 8). The clonal diversity in the particular
Stamaril® lot analysed in this study translated into a
Simpson 1-D index of about 0.042, in line with an
obvious diversity previously observed by others when
either comparing molecularly cloned cDNA fragments
of Stamaril® [52], or deep sequencing of another 17D-
204 vaccine [20], that yet escapes detection in consensus
sequences [28]. In each of the brains, one species
appeared to dominate. Only in the brain of one mouse
(that had been inoculated with 10−2 PFU) (Figure 2,
Brain 11) 2 major variants were detectable (Figure 4B
and Supplementary Figure S3). By contrast, in mice
that had been injected with 20 µg of plasmid encoding
a molecular clone of YFV-17D, the virus replicates to
low diversity and clustered as one homogenous virus
species, with no separate clonal linages of YFV-17D aris-
ing when comparing individual brains (Figure 5, Sup-
plementary Figure S4). Importantly, no obvious
selection for more aggressively growing virus variants
could be observed neither in vivo, nor regarding plaque
phenotype in vitro of the individual virus variants iso-
lated from mouse brains after neurotropic replication
Figure 3. Diversity of virus variants in brains of mice inoculated with YFV-17D and PLLAV. (A) Hamming distances calculated for 104
PFU [high inoculum] (n = 3, 29 clones), 10−1 PFU + 10−2 PFU [low inoculum] (n = 3, 44 clones) of YFV-17D, and PLLAV (n = 7, 86
clones). (B) Hamming distances computed for each virus inoculum. (C) The Shannon entropy and (D) Simpson’s index of diversity
for each inoculum. Data for PLLAV are from 2 independent experiments (n = 3 each), bars presented median values. Student t-test
for statistical comparison between groups.
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Figure 4. Evolutionary analysis and diversity of YFV-17D before and after inoculation in AG129 mice. (A) Diversity in plaque-puriﬁed
virus clones (n = 20) of Stamaril® (lot H5105) prior to injection in mice. A consensus sequence (Stamaril® P0) was generated from 20
plaque-puriﬁed virus clones. Evolutionary analysis in MEGA X [36] using Maximum Likelihood method and Kimura 2-parameter
model [51]. Tree by Neighbor-Join and BioNJ algorithms to a matrix of pairwise distances (Maximum Composite Likelihood esti-
mates), selecting the topology with superior log likelihood value (−15353.23). Branch lengths drawn to scale (scale bar: 0.0020
substitutions per site). The analysis involved n = 21 nucleotide sequences, including GenBank X03700 as reference genome,
with a total of 10862 positions in the ﬁnal dataset. (B) Graphical visualization of genetic diversity and segregation observed in
YFV-17D populations following neurotropic infection in AG129 mice.
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(Supplementary Figure S5). In conclusion, in mice that
had been inoculated with YFV-17D, the diversity
observed in brain-derived YFV-17D clones (Figure 3A-
D and Figure 5) is hence likely the consequence of pre-
existing heterogeneity in the YFV-17D inoculum (i.e.
Stamaril®) prior to injection (Figure 4A, Supplementary
Figure S3). Diversity stays very low if the inoculum con-
sists of a molecular clone of YFV-17D.
Discussion
The primary goal of the study was to assess the genetic
stability and diversity (mutation rates and patterns)
arising during YFV-17D replication in a vertebrate
host. We chose to analyse populations by sampling
and direct sequencing of representative numbers of
plaque-puriﬁed full virus genomes. This allowed to
assess and compare clonal sequence variability arising
during error-prone viral replication in vivo of the
licensed YFV-17D vaccine.
The two main substrains of YFV-17D currently
commercialized as vaccines are YF17D-204, and
YF17DD [17]. The evolution of YFV-17D live-attenu-
ated virus was monitored when it was either injected as
a viral inoculum directly derived from Stamaril® or
when the viral genome was launched as a clonal virus
Figure 5. Phylogenetic tree of Stamaril® and PLLAV-derived YFV-17D clones from AG129 mice. Coloured dots represent the diﬀer-
ent inocula. Green: PLLAV 20 µg; blue dots: 104 PFU Stamaril; yellow: 10−1 PFU Stamaril; red: 10−2 PFU Stamaril: purple: consensus
sequence (P0) of Stamaril®. Evolutionary history inferred using the Neighbor-Joining method [52]. The optimal tree (sum of branch
length = 0.00785397) drawn to scale. Evolutionary distances (in number of base substitutions/site) computed using the Kimura 2-
parameter method [17], involving n = 162 nucleotide sequences (n = 10862 positions in the ﬁnal dataset after pairwise deletion of
ambiguous positions).
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from a plasmid (PLLAV-YFV-17D, 17D-204 ATCC
strain). As the vertebrate host, we used IFN α/β and
γ-receptor deﬁcient AG129 mice; these animals are
hypersusceptible to infection with either YFV or
YFV-17D [55–57]. Inoculation of these mice with
YFV-17D (equivalent to a fractional dose of Stamaril®)
results, on average after 12 days, in a lethal dissemi-
nated and neuroinvasive infection. When very low
inocula are being used disease onset and mortality is
delayed, the mean day to euthanasia is then on average
16 days [57]. This model thus allows lengthy replica-
tion and expansion of the initial (minimal) inoculum
and is thus ideally suited to study evolution of the
viral population. Hamming distances, Shannon
entropy values and Simpson’s indices of diversity
reveal a relatively low viral diversity in mice inoculated
with a rather high inoculum (104) PFU of YFV-17D
(Figure 3). The diversity increases with decreasing
titres of the inoculum. We observed the highest diver-
sity in a mouse injected with a very low inoculum (10−2
PFU, corresponding to ∼1 CCID50) of YFV-17D. Virus
isolates from the brain of this mouse comprised a
mutant spectrum of at least eight diﬀerent virus var-
iants (out of 15 brain-derived isolates) that arose
from the parental Stamaril®. Virus isolates from the
low titre inoculum had increased Hamming distances
signiﬁcantly diﬀerent (p < 0.0001) compared with iso-
lates from the higher titre inoculum. In line with this
ﬁnding, the Shannon entropy and the Simpson’s
index of diversity were also higher for the low titre
compared to the high titre inoculum. This is unex-
pected considering that YFV is thought to reach the
brain through the blood brain barrier [58] whereby
an increase in the titre of the inoculum may possibly
increase the number of virus variants that would even-
tually reach the brain. A possible explanation may thus
be that the viruses present in the lowest titre inoculum
(< 1 PFU) may have replicated and evolved to generate
highly replication competent viruses; thereby possibly
selecting for variants with increased neuroinvasive
and neurovirulent properties. Though no direct exper-
imental evidence for this hypothesis could be provided
in this study, at least an increased infectious virus yield
(yet not viral RNA load) could be isolated from the
brains of the low versus the high titre infected groups
(Supplementary Figure S1B). The mice that had
received the low inoculum lived on average a couple
of days longer than those that had been injected with
a high titre inoculum [57]. A longer lifespan may also
allow more replication cycles/expansion of the popu-
lation, thereby increasing the likelihood of the acqui-
sition of novel mutations. It is worth noting that
variants that were originally present as minorities in
the heterogeneous Stamaril® population emerged to
be dominant variants orchestrating infection and
viral pathogenesis in some mice. This observation is
further suggestive for a viral bottleneck-mediated
quasispecies restriction [19] and subsequent evolution
of this variants. It has been reported that YFV does
not experience bottlenecks during its replication in
interferon type I (IFN α/β) deﬁcient mice [59]. How-
ever, as reported here (in an infection model wherein
each variant in the population has the potential of
infecting and causing disease), the population bottle-
neck may be a plausible phenomenon to explain the
neuroinvasion of the mouse brain by a single or at
most a few variants, in particular variants that existed
already in the inoculum as minorities. These ﬁndings
may have implications for WHÓs recent endorsement
of using fractional dosing to cope with vaccine shortage
during recent large emergency of YF epidemics (see
infra) [60].
To study the evolution of an expanding YFV-17D
population, yet starting from a homogenous inoculum,
we launched the virus as a clonal genome from a plas-
mid using our PLLAV technology [29]. From the low
diversity observed in these mice (Figure 2B), there is
no assumption to believe that launching of YFV-17D
replication from PLLAV-YFV-17D (driven by the cel-
lular RNA polymerase II) would add extra variability to
the circulating vaccine virus population [61,62]. In our
mouse model, PLLAV-launched YFV-17D had the
lowest diversity indices (Figure 3A,B); in fact, 42% of
the clones derived from the brain had no mutations
in their genomes whereas the remaining 58% carried
only 1–2 (mostly silent) mutations. This is in stark con-
trast to the situation where mice had been injected with
the vaccine virus (quasispecies); in that case, YFV-17D
clones carried up to 11 nucleotide variants per genome
(Figure 2A). Clones obtained from one of the PLLAV-
YFV-17D inoculated mice had a Shannon entropy and
Simpson index of diversity of zero, indicating that
YFV-17D can replicate without errors during broad
expansion in the vertebrate host. This ﬁnding is con-
trary to the popular paradigm that virus pathogenesis
increases with increasing viral diversity [21,62]. We
here show that diversity is not strictly necessary for
YFV-17D induced pathogenesis (the mouse without
virus diversity in the brain had equally overt signs of
infection/disease as mice carrying multiple variants).
In addition, clones isolated from another mouse that
had been injected with a low inoculum carried exclu-
sively silent mutations that likely do not change the
phenotype of the viruses (Supplementary Figure S5).
Furthermore, only one dominant virus variant (could
be isolated from each mouse brain (Supplementary
Figure S3; exception Brain 11) despite the high diver-
sity that pre-existed in the original YFV-17D (Sta-
maril®) inoculum, further corroborating that diversity
does not directly correlate with viral pathogenesis.
Our ﬁndings may have important public health
implications. The YF outbreaks in recent years
(Angola, DRC, Nigeria, and Brazil) repeatedly depleted
the YFV-17D vaccine stocks [60]. Consequently, WHO
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recommended fractional dosing (1/5) to meet the huge
demands. Studies demonstrate that reducing the dose
(of a suﬃciently high tittered) YFV-17D does not
aﬀect immunogenicity and safety, however, the studies
were restricted to adults [63–67]. Because of limited
data in children, WHO expressed potential safety con-
cerns and recommended full doses for children. WHO
highlighted the urgent need for more studies on frac-
tional YF doses in young children. Though our labora-
tory ﬁndings suggesting that YFV-17D accumulates
only very few mutations, even after maximal expansion
(following inoculation of an approximately < 1/105
human dose) in highly permissive mice cannot directly
be translated to the human situation in the ﬁeld, our
results suggest that the limited (one ﬁfth) fractional
dosing of YFV-17D may also in humans (most likely)
not result in an increased risk of YEL-AND, at least
not (to the experimental evidence provided by us and
others studying the genetic stability during YFV-17D
replication [20,49,68,69]) due to any apparent ten-
dency of the vaccine virus to revert to or select for
pathogenic variants. These results are also reassuring
for the use of fractional-dose YF vaccination in
children. A randomized non-inferiority trial was
recently launched comparing seroconversion after
fractional-dose in children (ClinicalTrials.gov number,
NCT02991495), to provide more data on immunogeni-
city and safety of low inoculum dose vaccination in this
vulnerable age group.
In conclusion, we conﬁrm that the mutation rate of
YFV-17D is very low, comprising between 10−4 and
10−5 nucleotide substitutions per genome following
long term maximal in vivo replication in the vertebrate
host. We provide evidence that pathogenesis of YFV-
17D (and possibly other ﬂaviviruses), does not necess-
arily correlate with virus diversity. The mutation fre-
quencies, Shannon entropies, Simpson indices of
diversity and the Hamming distances reveal that the
plasmid-launched YFV-17D is at least as stable (but
apparently obviously more stable), in immunodeﬁcient
mice, as the highly heterogeneous Stamaril® derived
virus. We also report that fractional dosing in AG129
mice does not aﬀect the stability and evolution of the
YFV-17D vaccine. Overall, the high genetic stability
of YFV-17D, even following maximal expansion in
the vertebrate host (here immunodeﬁcient mice) may
largely lower the risks of antigenic drift or evolution
of revertant virus vaccines.
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